Prognostic Index for Multiple Myeloma
Author Information
Author(s): G Grignani, PG Gobbi, R Formisano, C Pieresca, G Ucci, S Brugnatelli, A Riccardi, E Ascari
Primary Institution: Universita di Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy
Hypothesis
Can clinical characteristics at diagnosis and response to first-line chemotherapy improve the prognostic forecast in multiple myeloma patients?
Conclusion
The study proposes a new scoring system that effectively identifies different risk classes among multiple myeloma patients, improving prognosis estimation.
Supporting Evidence
- The proposed scoring system identified three risk classes with median overall survival of 52, 28, and 13 months.
- Three variables were found to be independently significant: the British Medical Research Council staging system, bone marrow plasma cell percentage, and response to therapy.
- Statistical analysis showed that the new prognostic model was highly significant.
Takeaway
Doctors can better predict how long patients with multiple myeloma will live by looking at their initial health and how they respond to treatment.
Methodology
231 patients were randomized in a multicenter trial to different therapies based on their disease stage, and their clinical features were analyzed for prognostic variables.
Limitations
The study's findings may not apply to all multiple myeloma patients due to the heterogeneity of the disease.
Participant Demographics
{"mean_age":65,"male":120,"female":111}
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website